In mouse melanoma, this was first revealed through a CRISPR knockout screen, where Mbnl1 and Mbnl2 emerged as top hits conferring tumor resistance to cytotoxic T cell-mediated killing [15]. This evidence concerns the gene MBNL2 and neoplasm.